Cargando…
Long-Term Disease Control of a Pancreatic Neuroendocrine Tumor with Lanreotide Autogel(®): A Case Report
The CLARINET study (ClinicalTrials.gov: NCT00353496) showed that somatostatin analogs are able to stabilize tumor growth in patients with intestinal and pancreatic neuroendocrine tumors (NETs). Here, we present a case of NET originating from the pancreatic tail that was treated with lanreotide Autog...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
S. Karger AG
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4224256/ https://www.ncbi.nlm.nih.gov/pubmed/25408662 http://dx.doi.org/10.1159/000368207 |
_version_ | 1782343322223771648 |
---|---|
author | Lybaert, Willem Van Hul, Erik Woestenborghs, Heidi |
author_facet | Lybaert, Willem Van Hul, Erik Woestenborghs, Heidi |
author_sort | Lybaert, Willem |
collection | PubMed |
description | The CLARINET study (ClinicalTrials.gov: NCT00353496) showed that somatostatin analogs are able to stabilize tumor growth in patients with intestinal and pancreatic neuroendocrine tumors (NETs). Here, we present a case of NET originating from the pancreatic tail that was treated with lanreotide Autogel(®). A 60-year-old patient underwent resection of a pancreatic NET with splenectomy and distal pancreatectomy. Four months after surgery, there was an increase in chromogranin A levels, along with a hypercaptating lesion of approximately 3.5 cm at the residual part of the pancreatic corpus. Treatment with 30 mg monthly-administered octreotide long-acting release (LAR) was initiated. After 3 months of treatment, a control CT scan revealed diffuse metastases in the liver, although the patient presented no symptoms and liver tests were normal. Due to difficulties with the administration of octreotide LAR, treatment was switched to lanreotide Autogel(®) 120 mg, administered as monthly deep-subcutaneous injections. Progression-free survival, as shown by 3-monthly CT scans, was obtained for 2 years without the need to increase the lanreotide Autogel(®) dose, and the patient reported no side effects. After these 2 years, deterioration of the patient's clinical status and weight loss were observed, along with increased size of the liver lesions and appearance of peritoneal metastases. Chemotherapy treatment with cisplatinum-etoposide was initiated, while the lanreotide Autogel(®) injections were continued. After three chemotherapy cycles, a rapid decline in the patient's quality of life was noted, and she requested discontinuation of the chemotherapy and lanreotide injections. One month later, the patient died due to clinical progressive disease. |
format | Online Article Text |
id | pubmed-4224256 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | S. Karger AG |
record_format | MEDLINE/PubMed |
spelling | pubmed-42242562014-11-18 Long-Term Disease Control of a Pancreatic Neuroendocrine Tumor with Lanreotide Autogel(®): A Case Report Lybaert, Willem Van Hul, Erik Woestenborghs, Heidi Case Rep Oncol Published online: September, 2014 The CLARINET study (ClinicalTrials.gov: NCT00353496) showed that somatostatin analogs are able to stabilize tumor growth in patients with intestinal and pancreatic neuroendocrine tumors (NETs). Here, we present a case of NET originating from the pancreatic tail that was treated with lanreotide Autogel(®). A 60-year-old patient underwent resection of a pancreatic NET with splenectomy and distal pancreatectomy. Four months after surgery, there was an increase in chromogranin A levels, along with a hypercaptating lesion of approximately 3.5 cm at the residual part of the pancreatic corpus. Treatment with 30 mg monthly-administered octreotide long-acting release (LAR) was initiated. After 3 months of treatment, a control CT scan revealed diffuse metastases in the liver, although the patient presented no symptoms and liver tests were normal. Due to difficulties with the administration of octreotide LAR, treatment was switched to lanreotide Autogel(®) 120 mg, administered as monthly deep-subcutaneous injections. Progression-free survival, as shown by 3-monthly CT scans, was obtained for 2 years without the need to increase the lanreotide Autogel(®) dose, and the patient reported no side effects. After these 2 years, deterioration of the patient's clinical status and weight loss were observed, along with increased size of the liver lesions and appearance of peritoneal metastases. Chemotherapy treatment with cisplatinum-etoposide was initiated, while the lanreotide Autogel(®) injections were continued. After three chemotherapy cycles, a rapid decline in the patient's quality of life was noted, and she requested discontinuation of the chemotherapy and lanreotide injections. One month later, the patient died due to clinical progressive disease. S. Karger AG 2014-09-26 /pmc/articles/PMC4224256/ /pubmed/25408662 http://dx.doi.org/10.1159/000368207 Text en Copyright © 2014 by S. Karger AG, Basel http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article licensed under the terms of the Creative Commons Attribution-NonCommercial 3.0 Unported license (CC BY-NC) (www.karger.com/OA-license), applicable to the online version of the article only. Users may download, print and share this work on the Internet for noncommercial purposes only, provided the original work is properly cited, and a link to the original work on http://www.karger.com and the terms of this license are included in any shared versions. |
spellingShingle | Published online: September, 2014 Lybaert, Willem Van Hul, Erik Woestenborghs, Heidi Long-Term Disease Control of a Pancreatic Neuroendocrine Tumor with Lanreotide Autogel(®): A Case Report |
title | Long-Term Disease Control of a Pancreatic Neuroendocrine Tumor with Lanreotide Autogel(®): A Case Report |
title_full | Long-Term Disease Control of a Pancreatic Neuroendocrine Tumor with Lanreotide Autogel(®): A Case Report |
title_fullStr | Long-Term Disease Control of a Pancreatic Neuroendocrine Tumor with Lanreotide Autogel(®): A Case Report |
title_full_unstemmed | Long-Term Disease Control of a Pancreatic Neuroendocrine Tumor with Lanreotide Autogel(®): A Case Report |
title_short | Long-Term Disease Control of a Pancreatic Neuroendocrine Tumor with Lanreotide Autogel(®): A Case Report |
title_sort | long-term disease control of a pancreatic neuroendocrine tumor with lanreotide autogel(®): a case report |
topic | Published online: September, 2014 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4224256/ https://www.ncbi.nlm.nih.gov/pubmed/25408662 http://dx.doi.org/10.1159/000368207 |
work_keys_str_mv | AT lybaertwillem longtermdiseasecontrolofapancreaticneuroendocrinetumorwithlanreotideautogelacasereport AT vanhulerik longtermdiseasecontrolofapancreaticneuroendocrinetumorwithlanreotideautogelacasereport AT woestenborghsheidi longtermdiseasecontrolofapancreaticneuroendocrinetumorwithlanreotideautogelacasereport |